Functional mesoporous silica nanoparticles towards oral delivery of insulin Claudia Iriarte Mesa 1 , Estelle Juère 1,2, , Endre Kiss 3 , Andrea Bileck 4 , Christopher Gerner 4 , Doris Marko 3 , Giorgia Del Favero 3 and Freddy Kleitz 1 1 Department of Inorganic Chemistry, University of Vienna, Austria, 2 APC - Applied Process Company, Dublin, Ireland, 3 Department of Food Chemistry and Toxicology, Faculty of Chemistry, University of Vienna, Austria, 4 Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Austria Despite more than a century of research to achieve oral delivery insulin, the current clinical reality remains unchanged in terms of therapeutic administration, due to the challenge of overcoming gastrointestinal barriers. [1] The use of dendritic mesoporous silica nanoparticles (DMSNs) together with a protein-based excipient, succinylated b-lactoglobulin (BL), has allowed to obtain pH-responsive tablets, preventing premature gastric release and degradation of encapsulated insulin. [2] However, there are still open issues related to colloidal stability, control of release rate, permeation enhancement and mucoadhesion, which need to be addressed before reaching in vivo tests. To this aim, we focus our studies on the examination of the influence of surface chemistry/charge and colloidal stability of DMSNs on the loading efficiency and insulin release performances. For this, DMSNs (130 nm; pore size: 7.0 nm) were functionalized with polyethylene glycol (PEG, 2 kDa) and a phosphonate-silane, trihydroxysilylpropyl methylphosphonate (THMP), introduced through different post-grafting strategies. [3,4] The functionalized DMSNs (DMSNs-PEG and DMSNs-PO 3 ) exhibited enhanced colloidal stability in aqueous and saline media (PBS) over a wide pH range. Different formulations for oral administration were prepared by mixing BL with pure and functionalized DMSNs containing insulin (20% w/w) and preliminary release tests were performed with simulated body fluids. [2] Compared to a DMSNs-free formulation, encapsulated insulin was even more protected and the release was lowered down to acceptable threshold (less than 10%) at pH 1.2, while at pH 7.4 controlled release could be reached for 24 h. The analysis of the released insulin confirmed that drug confinement into the pores of the hybrid DMSNs did not affect the peptide structure. The ability of DMSNs to be internalized by intestinal cells was tested using non-transformed human epithelial colon cells (HCEC) through live cell imaging, intracellular insulin quantification and benchmarking the biological activity of insulin uptake with respective cell metabolic status. References 1. Y. Xiao, Z. Tang, J. Wang, C. Liu, N. Kong, O. C. Farokhzad, W. Tao, Angew. Chemie - Int. Ed. 2020 , 59, 19787–19795. 2. E. Juère, R. Caillard, D. Marko, G. Del Favero, F. Kleitz, Chem. - A Eur. J. 2020 , 26, 5195–5199. 3. C. Von Baeckmann, R. Guillet-Nicolas, D. Renfer, H. Kählig, F. Kleitz, ACS Omega 2018 , 3, 17496–17510. 4. M. Bouchoucha, M. F. Côté, R. C-Gaudreault, M. A. Fortin, F. Kleitz, Chem. Mater. 2016 , 28, 4243–4258.
L20
© The Author(s), 2021
Made with FlippingBook Learn more on our blog